Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells

Histone deacetylase inhibitors (HDACi) were identified nearly four decades ago based on their ability to induce cellular differentiation. However, the clinical development of these compounds as cancer therapies has focused on their capacity to induce apoptosis in hematologic and lymphoid malignancie...

Full description

Saved in:
Bibliographic Details
Main Authors: Cain, Jason E., McCaw, Andrew, Jayasekara, W. Samantha N., Rossello, Fernando J., Marini, Kieren D., Irving, Aaron T., Kansara, Maya, Thomas, David M., Ashley, David M., Watkins, D. Neil
Format: Artigo
Language:Inglês
Published: Hindawi Publishing Corporation 2013
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3603321/
https://ncbi.nlm.nih.gov/pubmed/23533324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2013/608964
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items